Clinical Study
Clinical Study Results
Results
Research Sponsor: MedImmune, LLC
Drugs Studied: MEDI4166
National Clinical Trial #: NCT02524782
Protocol #: D6240C00001
Study Date: October 2015 to April 2017
Short Study Title: A study in participants with type 2 diabetes to see how MEDI4166
affects the blood sugar (glucose) levels and the amount of bad
cholesterol (LDLc) in the body and if MEDI4166 is safe to take
Thank you!
Thank you for taking part in the clinical study for the drug MEDI4166. This drug is being
developed to lower blood sugar and bad cholesterol in patients with type 2 diabetes.
You and all of the participants helped researchers learn how MEDI4166 affects the blood
sugar levels and the amount of bad cholesterol in participants and if MEDI4166 causes
medical problems.
MedImmune, LLC sponsored this study and thinks it is important to share the results of the
study with you and the public. An independent, non-profit organization called CISCRP and
a medical writing organization called Synchrogenix helped prepare this summary of the
study results. We hope it helps you understand and feel proud of your important role in
medical research.
If you participated in the study and have questions about the results, please speak with the
doctor or staff at your study site.
What is happening with the study now?
The study had 2 parts: Part A and Part B.
In Part A, participants were in the study for up to 12 weeks and got 1 total dose.
In Part B, participants were in the study for up to 17 weeks and got multiple doses.
The study started in October 2015 and ended in April 2017. The study included
103 participants at 11 study sites in the United States.
Part A included 40 participants. Part B included 63 participants.
When the study ended, the sponsor reviewed the data and created a report of the results.
This is a summary of that report.
1